Holen Sie sich die Stockscreener-App
173.12
0.68%
1.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$172.00
Offen:
$171.17
24-Stunden-Volumen:
1.97M
Relative Volume:
0.46
Marktkapitalisierung:
$122.48B
Einnahmen:
$24.78B
Nettoeinkommen (Verlust:
$3.68B
KGV:
33.46
EPS:
5.1743
Netto-Cashflow:
$5.29B
1W Leistung:
+3.67%
1M Leistung:
-2.30%
6M Leistung:
-24.20%
1J Leistung:
-6.16%
1-Tages-Spanne:
$169.88
$173.65
1-Wochen-Bereich:
$164.10
$174.95
52-Wochen-Spanne:
$160.93
$242.80
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Compare DHR vs TMO, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
173.04 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
TMO
Thermo Fisher Scientific Inc
|
449.24 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
IDXX
Idexx Laboratories Inc
|
557.96 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
340.21 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.27 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
RBC Capital Resumes Coverage of Danaher Corporation (DHR) - Insider Monkey
Danaher Corp. stock (US2358511028): dividend timeline and institutional interest in focus - AD HOC NEWS
Danaher Corp. May Be the Smartest Bet in Biotech Right Now - AOL.com
Cytiva introduces next-gen Biacore 8 series SPR systems for drug discovery - BioSpectrum Asia
Masimo earnings in focus as Danaher deal nears close - Investing.com
Danaher Raises $3 Billion in Record Private-Placement Bond Sale - Bloomberg.com
Danaher Targets Carbon Capture And AI CMC To Shape Long Term Growth - Yahoo Finance
Danaher (DHR) Stock Price, News & Analysis $DHR - MarketBeat
Danaher stock (US2358511028): diagnostics spin?off and Q1 earnings reshape the portfolio - AD HOC NEWS
Danaher Corp. stock (US2358511028): earnings beat keeps focus on life sciences recovery - AD HOC NEWS
Research Tools & Consumables Stocks Q1 Results: Benchmarking Danaher (NYSE:DHR) - Barchart.com
Danaher Corp. stock outperforms competitors on strong trading day - MarketWatch
Eagle Capital Management Bet on Danaher (DHR) for Its Mid-Teens EPS Growth - Yahoo Finance
Tissue Diagnostics Market to Reach USD 9.33 Bn by 2031 Driven by Expanding Precision Oncology Applications and Rising Adoption of Digital Pathology, Says Mordor Intelligence - GlobeNewswire Inc.
Danaher stock (US2358511028): spin-off, diagnostics focus and what the latest numbers reveal - AD HOC NEWS
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead? - The Globe and Mail
Pall to Address a Key Decarbonization Challenge with Additively Manufactured Filtration - Carroll County Mirror-Democrat
Why The Narrative Around Danaher (DHR) Is Shifting With Bioprocess Recovery And Masimo Deal - Yahoo Finance
Danaher Corp. stock (US2358511028): insider awards highlight leadership confidence after guidance li - AD HOC NEWS
Danaher (NYSE: DHR) director Linda Filler receives stock and option grants - Stock Titan
Danaher (NYSE: DHR) SVP uses 281 shares for tax withholding, retains 8,291 - Stock Titan
[Form 4] DANAHER CORP /DE/ Insider Trading Activity - Stock Titan
Alan G. Spoon (DHR) awarded RSUs and stock options in new Danaher Form 4 - Stock Titan
Danaher (NYSE: DHR) director awarded RSUs and long-dated stock options - Stock Titan
Danaher (NYSE: DHR) director Teri List granted RSUs and stock options as board compensation - Stock Titan
Danaher (NYSE: DHR) awards director Zerhouni RSUs and stock options - Stock Titan
Danaher (NYSE: DHR) director granted RSUs and options in new award - Stock Titan
Danaher (DHR) director Charles Lamanna awarded RSUs and 1,699-share option - Stock Titan
Danaher shares climb as analysts turn more constructive after Q1 guidance lift - Quiver Quantitative
Danaher Corp. stock (US2358511028): restructuring after spin-off, new focus on life sciences - AD HOC NEWS
Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR - MarketBeat
Danaher stock (US2358511028): Q1 figures, dividend and analyst views in focus - AD HOC NEWS
Danaher stock (US2358511028): earnings momentum and dividend in focus for US investors - AD HOC NEWS
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech spec - AD HOC NEWS
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks - Insider Monkey
Danaher Masimo Deal Shifts Growth Outlook And Investor Focus - Yahoo Finance
DoorDash Inc stock (US2358511028): Q1 2026 profit beat keeps growth story in focus - AD HOC NEWS
Danaher Corporation Trade Ideas — AQUISEU:DAPD - TradingView
Danaher Valuation Reset Highlights Recurring Revenues And Lean Operating Framework - Yahoo Finance
Danaher Seen on Path to Growth Reacceleration on Bioprocess Recovery, RBC Says - marketscreener.com
DHR Reinstated by RBC Capital -- Price Target Set at $200 - GuruFocus
Danaher Stock: Analyst Estimates & Ratings - Barchart
Danaher stock (US2358511028): spin-offs reshape the medtech group after latest quarterly numbers - AD HOC NEWS
Danaher (DHR) Receives Outperform Rating from RBC Capital with $200 Price Target - GuruFocus
RBC Capital assumes Danaher stock coverage with outperform rating - Investing.com UK
RBC Capital assumes Danaher stock coverage with outperform rating By Investing.com - Investing.com Nigeria
DoorDash Inc stock (US2358511028): investors weigh latest results and US food delivery outlook - AD HOC NEWS
Jim Cramer Discusses the Performance of Danaher and Its Peers - Insider Monkey
Danaher stock (US2358511028): Shares decline amid four-day losing streak - AD HOC NEWS
The Escalator: Rx&O, Danaher, Ruder Finn and more - Medical Marketing and Media
Transcript : Danaher Corporation Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11 - marketscreener.com
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):